TAG:
specialty laboratories
Private Equity Firms: Ready to Buy More Labs?
By Robert Michel | From the Volume XII No. 16 – November 14, 2005 Issue
CEO SUMMARY: Times are good in the laboratory industry. At least that’s the opinion of a growing number of professional investors. They are searching throughout the country for laboratories to acquire. They are motivated by the consistent financial performance of many lab companies, bot…
AmeriPath Will Acquire Specialty Laboratories
By Robert Michel | From the Volume XII No. 14 – October 3, 2005 Issue
CEO SUMMARY: It’s a surprise to most lab industry observers. AmeriPath, a company built around 400 anatomic pathologists working mostly in community hospitals, is acquiring a national reference/esoteric testing company. However, this deal may be better understood by looking at the motiv…
“August 1, 2005 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XII No. 11 – August 1, 2005 Issue
Redwood City, California-based Genomic Health, Inc. is considering an initial public offering (IPO) to raise as much as $75 million. The company filed preliminary documents with the Securities and Exchange Commission (SEC) on July 15, 2005. In January 2004, Genomic H…
“May 30, 2005 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XII No. 8 – May 30, 2005 Issue
It’s been a revolving door for senior executives at Specialty Laboratories, Inc. during the past seven weeks. Gone by resignation is CFO Kevin Sayer (effective May 16). Gone by elimination of positions are Dan R. Angress, Sr. VP/Business Development (April 8) and Cynthia K. French,…
“Lowest-Priced” Chickens Came Home to Roost
By R. Lewis Dark | From the Volume XII No. 4 – March 7, 2005 Issue
IN READING THE INTELLIGENCE BRIEFINGS on reference/esoteric laboratories in this issue, I found it interesting that American Medical Laboratories (AML) is no longer an independent lab company serving this market segment and that, of the four remaining independent lab companies focuse…
Profit Squeeze Pressures Specialty Laboratories
By Robert Michel | From the Volume XII No. 4 – March 7, 2005 Issue
CEO SUMMARY: Despite much success and milestones at Specialty Laboratories during the past 36 months, it has yet to achieve the most important goal of all: net profits. One reason is familiar to all laboratory administrators and pathologists: with its existing fixed overhead and cost stru…
National Reference Labs Undergoing Changes
By Robert Michel | From the Volume XII No. 4 – March 7, 2005 Issue
CEO SUMMARY: Maybe it’s a coincidence. More likely it is a response to changes in the reference/esoteric marketplace. Specialty, Esoterix, ARUP, and Mayo have each recently reassessed their core strategies and are shifting their business emphasis. Because three of these four companies a…
Review of 2004 Lab Sales Identifies Buyer Interest
By Robert Michel | From the Volume XII No. 3 – February 14, 2005 Issue
CEO SUMMARY: Laboratory acquisition activity was surprisingly high during 2004. One reason is that new buyers appeared in the marketplace. However, all buyers have specific acquisition criteria. When a selling lab meets that criteria, it can expect multiple bidders and a strong purchase p…
Bi-Annual Look at Trends Reshaping Clinical Labs
By Robert Michel | From the Volume XII No. 2 – January 24, 2005 Issue
CEO SUMMARY: Among other things, we declare the end to the heyday of the independent commercial lab company which offers a broad test menu to all types of office-based physicians. In its place springs forth the specialty or niche testing laboratory. Small and focused on a specific number …
Florida Medicaid Contract Is On-Again, Off-Again
By Robert Michel | From the Volume XII No. 1 – January 3, 2005 Issue
CEO SUMMARY: Start with a flawed idea: Medicaid lab testing costs in Florida can be cut by awarding an exclusive statewide contract to one laboratory company. Compound that bad idea by designing a contract awards process that guarantees the state will pay twice for a number of tests while…
CURRENT ISSUE
Volume XXXI, No. 14 – October 14, 2024
For the second time in the past 16 months, respected health systems have taken steps to collaborate specifically to advance value-based care. Also, several statewide pilot programs—each involving tens of thousands of newborns—are publishing studies that demonstrate how exome, whole genome sequencing, and rapid whole genome sequencing can deliver both improved patient outcomes and a return on investment.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized